(Q64350429)
Statements
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week (English)
0 references
March 2014
0 references
January 2016
0 references
97
0 references
18 year
0 references
65 year
0 references